Images List Premium Download Classic

Alcoholic Fatty Liver

Alcoholic Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical compositions for combination therapy
Intercept Pharmaceuticals, Inc.
January 11, 2018 - N°20180008616

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e. G., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (...
Treatment for non-alcoholic fatty liver diseases
Dsm Ip Assets B.v.
January 04, 2018 - N°20180000775

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic ...
Grape seed products for nonalcoholic fatty liver disease and other uses
The United States Of America, As Represented By The Secretary Of Ariculture
December 28, 2017 - N°20170368128

Embodiments described herein provide for uses of grape products, such as chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing nafld, and other embodiments and uses as described herein.
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating intestinal hyperpermeability
Merck Sharp & Dohme Corp.
December 21, 2017 - N°20170360736

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic ...
Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
Ucl Business Plc
December 14, 2017 - N°20170354627

Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (hscs), such as non-alcoholic fatty liver disease (nafld), fibrosis, and liver cancer, using ammonia-lowering therapies.
Biaryl derivative as gpr120 agonist
Lg Chem, Ltd.
December 07, 2017 - N°20170349594

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory ...
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
November 30, 2017 - N°20170340699

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of adenovirus 36 e4orf1 protein or functional variant thereof.
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
November 30, 2017 - N°20170340661

The present invention relates to rnai agents, e. G., double stranded rnai agents, targeting the patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such rnai agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.
Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome
Duke University
November 16, 2017 - N°20170326199

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2.
Compositions and methods for lipid metabolism disorder
Duke University
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
The Regents Of The University Of California
October 26, 2017 - N°20170304233

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash).
Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic ...
The Regents Of The University Of California
October 19, 2017 - N°20170298117

The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting glp-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side ...
Methods of lowering serum cholesterol
The Regents Of The University Of California
October 19, 2017 - N°20170296653

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided.
Alcoholic Fatty Liver Patent Pack
Download + patent application PDFs
Alcoholic Fatty Liver Patent Applications
Download + Alcoholic Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Alcoholic Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of ...
Sancilio & Company, Inc.
September 14, 2017 - N°20170258752

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either ...
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Somalogic, Inc.
August 10, 2017 - N°20170227550

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
A peptide therapy to counteract insulin resistance and type 2 diabetes
Indian Institute Of Technology Madras
July 27, 2017 - N°20170209544

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well.
Prevention and treatment of non-alcoholic fatty liver disease
Ohio University
July 13, 2017 - N°20170196845

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective ...
Inhibitors of the farnesoid x receptor and uses in medicine
The Penn State Research Foundation
June 01, 2017 - N°20170152283

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier ...
Calcitonin mimetics for treating diseases and disorders
The Penn State Research Foundation
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
Loading